Some 60 times in the past few years, Indianapolis drug maker Eli Lilly and Co. has looked to companies in biotech havens like San Francisco to develop promising discoveries that don't fit its business strategy.
Indianapolis simply did not have the high-risk venture capital needed to fund the start-up companies that could take these ideas to market.
Until now, that is.
lY573144 could spark Indiana's life-science economy | IndyStar.com
No comments:
Post a Comment